Clinical trial
A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00556959 is registered in ClinicalTrials.gov with Addrenex Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
- Lead sponsor
- Addrenex Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- August 31, 2008
- Enrollment
- 236 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.